Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    Scopus BioPharma Inc. logo
    SCPS

    Scopus BioPharma Inc.

    MaveScore 34 Low model confidence
    Last Price US$0.00 As of Jun 15, 2026
    Market Cap US$15900.000000000002 Company size context
    7D Performance -33.33% Past 7 days
    1Y Performance 33.33% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Dec 31, 2023

    898 days old

    Market price date

    Jun 15, 2026

    1 day old

    Coverage

    14/16

    2 missing model inputs

    Data quality

    Review

    Partial or delayed snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 34 Low confidence

    Stored data quality

    Freshness and coverage checks

    Stored company inputs are available, but some dates or model fields are older or incomplete.

    14/16 Partial or delayed snapshot

    Quality

    Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.

    12/35 Weak

    Financial Strength

    Financial strength rewards durable profitability, margins, and positive free cash flow.

    12/25 Mixed

    Valuation Support

    Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.

    5/15 Weak

    Momentum

    Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    5/15 Weak

    Shareholder Alignment

    Shareholder alignment rewards less dilutive share behavior and enough size for liquid research coverage.

    0/10 Weak

    Positive model output

    More live company inputs are needed before positive research signals can be surfaced.

    Research risks to review

    • Quality score blends the latest weighted model rank with underlying profitability and dilution ranks.
    • Valuation favors positive earnings, positive cash flow, and lower price-to-book multiples.
    • Momentum highlights research candidates with supportive 3-month and 6-month price regimes.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting. Missing inputs right now include net margin, gross margin.

    Overview Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Ratio
    Dashboard Funda..tals Deep..lue Prediction Screener Map

    Scopus BioPharma Inc. Overview

    Industry: Biotechnology

    Sector: Healthcare

    Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

    Scopus BioPharma Inc. is evaluated using Mavefund's quality framework: growing earnings, durable profit margins, conservative leverage, strong return on equity, and disciplined share repurchases.

    Score

    Price History & Performance

    Review Scopus BioPharma Inc. in context before unlocking the interactive price chart, financial overlays, and downloadable ratio tables.

    Recent News



    Scopus BioPharma Inc. Competitors

    Scopus BioPharma Inc. operates in the Biotechnology industry within the Healthcare sector. Unlock the full page to compare peer rankings, valuation quality, profitability, leverage, and growth trends.

    Earnings Per Share

    EPS quality is one of the core Mavefund signals. Sign up to continue into the detailed EPS, ROE, margin, share buyback, leverage, and financial ratio analysis.

    Continue the analysis

    Sign up to unlock ROE, net margin, share buyback, leverage, financial ratios, peer charts, and downloads.

    View plans
    Ticker Image

    Scopus BioPharma Inc.

    US$0.00

    US$15900.000000000002

    -33.33%

    33.33%